{
    "id": 18310,
    "fullName": "BCL6 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BCL6 positive indicates the presence of the BCL6 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 604,
        "geneSymbol": "BCL6",
        "terms": [
            "BCL6",
            "BCL5",
            "BCL6A",
            "LAZ3",
            "ZBTB27",
            "ZNF51"
        ]
    },
    "variant": "positive",
    "createDate": "02/19/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FX1 inhibited growth of Bcl6-dependent diffuse large B-cell lymphoma cell lines in culture and induced tumor shrinkage in cell line xenograft models (PMID: 27482887).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 4815,
                "therapyName": "FX1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6759,
                    "pubMedId": 27482887,
                    "title": "Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27482887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8806,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FX1 enhanced response to Adriamycin (doxorubicin) in both germinal center B cell and activated B cell subtypes of diffuse large B-cell lymphoma cell lines in culture (PMID: 27482887).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 4816,
                "therapyName": "Doxorubicin + FX1",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6759,
                    "pubMedId": 27482887,
                    "title": "Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27482887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 79-6 inhibited viability of BCL6-dependent diffuse large B-cell lymphoma (DLBCL) cell lines and BCL6-expressing primary DLBCL cells in culture, and reduced tumor volume and increased apoptosis in BCL6-dependent DLBCL cell line xenograft models (PMID: 20385364).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 5339,
                "therapyName": "79-6",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7892,
                    "pubMedId": 20385364,
                    "title": "A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20385364"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10004,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 79-6 increased E-cadherin expression, and decreased growth and invasion of BCL6-expressing breast cancer cell lines in culture (PMID: 12944904).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 5339,
                "therapyName": "79-6",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7894,
                    "pubMedId": 12944904,
                    "title": "BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12944904"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7236,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells expressing BCL6 demonstrated sensitivity to treatment with RI-BPI in culture and in xenograft models, resulting in decreased cell survival and reduced tumor burden (PMID: 18927431).",
            "molecularProfile": {
                "id": 18649,
                "profileName": "BCL6 positive"
            },
            "therapy": {
                "id": 4425,
                "therapyName": "RI-BPI",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6245,
                    "pubMedId": 18927431,
                    "title": "A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18927431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18649,
            "profileName": "BCL6 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}